Loading...
Loading...
AMTI| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 19.7M |
| Operating I/L | -28.5M |
| Other Income/Expense | 0.6M |
| Interest Income | 0.6M |
| Pretax | -27.9M |
| Income Tax Expense | -1.1M |
| Net Income/Loss | -26.8M |
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company specializing in the design and development of oral and respiratory biologic product candidates for autoimmune, inflammatory, and metabolic diseases. Their lead product candidate, AMT-101, is an oral fusion of rhIL-10 in Phase II clinical trial for ulcerative colitis treatment. Additionally, they are developing AMT-126, an oral fusion of interleukin 22, in Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company's revenue model is based on the development and commercialization of oral biologic therapeutic modalities, including peptides, proteins, antibodies, antibody fragments, and RNA therapeutics.
